Emerging studies suggest Retatrutide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could offer a significant development for body loss . Initial clinical investigations have indicated substantial reductions in visceral tissue, conceivably exceeding other body composition therapies . However… Read More